Fotovat-Ahmadi Navid, Siddiqui Omer, Ong Joshua, Thanitcul Chanon, Reinhardt Christian, Cologna Stephanie M, Aakalu Vinay Kumar
Department of Ophthalmology and Visual Sciences, University of Michigan Kellogg Eye Center, Ann Arbor, MI, United States.
Department of Chemistry, University of Illinois at Chicago, Chicago, IL, United States.
Ocul Surf. 2025 Jul;37:283-300. doi: 10.1016/j.jtos.2025.05.005. Epub 2025 May 8.
The tear film is a complex structure with rich interactions with the human body. A growing body of evidence suggests that measuring changes in protein, lipid, or other metabolite concentration in the tear film can be used to help detect disease. Particularly in the era of precision medicine, the tear film serves as a promising source of non-invasive insights into systemic health for early diagnosis and treatment. This paper analyzes the latest research in tear film biomarkers for systemic diseases. The review was conducted through PubMed and Embase databases using the PRISMA protocol and includes 54 articles. This paper first reviews the anatomy and physiology of tear film, as well as the latest proteomic analysis techniques on the tear film. We then provide a disease-by-disease review on the tear film as a biomarker including 5 articles related to Alzheimer's Disease, 10 articles related to Cancers, 1 article related to Cystic Fibrosis, 1 article related to Migraines, 4 articles related to Multiple Sclerosis, 15 articles related to Parkinson's Disease, 7 articles related to Rheumatoid Arthritis, and 11 articles related to Thyroid Disease. This paper highlights the promising results of these studies yet also reviews the challenges with limited sample sizes, reproducibility, and biological understanding of biomarkers. We conclude this paper with insights for future work to ensure clinical validity and generalizability. Ultimately, the tear film is a clinically accessible, complex structure that provides a wealth of information that may contribute to a more comprehensive understanding of systemic health.
泪膜是一种与人体有着丰富相互作用的复杂结构。越来越多的证据表明,测量泪膜中蛋白质、脂质或其他代谢物浓度的变化可用于帮助检测疾病。特别是在精准医学时代,泪膜作为一种有前景的非侵入性来源,可为全身健康的早期诊断和治疗提供见解。本文分析了泪膜生物标志物用于全身性疾病的最新研究。该综述通过PubMed和Embase数据库按照PRISMA协议进行,共纳入54篇文章。本文首先回顾了泪膜的解剖学和生理学,以及泪膜的最新蛋白质组学分析技术。然后,我们针对泪膜作为生物标志物的情况逐病进行综述,包括5篇与阿尔茨海默病相关的文章、10篇与癌症相关的文章、1篇与囊性纤维化相关的文章、1篇与偏头痛相关的文章、4篇与多发性硬化症相关的文章、15篇与帕金森病相关的文章、7篇与类风湿性关节炎相关的文章以及11篇与甲状腺疾病相关的文章。本文强调了这些研究的有前景的结果,但也回顾了样本量有限、可重复性以及对生物标志物的生物学理解等方面的挑战。我们在本文结尾给出了对未来工作的见解,以确保临床有效性和可推广性。最终,泪膜是一种临床上可获取的复杂结构,它提供了丰富的信息,可能有助于更全面地了解全身健康。